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$214 PT, Affeetioe disorders and ant~depre~sam~ 
/n=2/, delirium /n=l/)  reoccured after IFN-a dosing has been 
replaced. In the medical history of the patients we found 9 cases 
of psychiatric diseases: depressive disorders (n=5), somatoform 
disorder (n=l),  agoraphobia without panic attack (n=3). In all the 
cases of depressions the previous mood disorders recurred during 
the IFN-a treatment. Patients with former agoraphobia developed 
panic attacks and depressive symtoms, The psychiatric sequeles 
oceured earlier in patients with positive medical history (mean: 
2.9 months) than in other patients (mean: 6.6 months). All of 
the 37 patients received psychopharmacotherapy: antidepressives 
(n=31), anxiolytics (n=4), antidepressives plus anxiolytics (n=20), 
antipsychotics (n=3). In 6 cases (16,2%) the IFN-a were stopped, 
7 patients (18,9%) underwent a dose reduction and 21 patients 
(56,7%) could continue the therapy with primary dose. 3 patients 
were lost from follow-up. All patients who were dropped out 
of IFN-a treatment fully recovered from psychiatric syndromes 
(delirium/n=2/, depression/n=3/, panic /n=l / ) .  
Conclusions: Depressions were found to be the most frequent 
psychiatric complication, but other syndromes (especially anxiety 
disorders) also occured. Our results present that previous mental 
disorders can hasten the outbreak of the IFN-a induced psychi- 
atric symptoms. Psyehopharmacotherapies proved to be effective, 
therefore dose reduction or drop-out of IFN-a was avoidable in 
the majority of cases. These results show the necessity of the 
collaboration between physicians and psychiatrists in the case of 
all IFN-a treated patients. The examination of CNS effects of 
the IFN-a can contribute the research of the cytokine network, 
especially its role in the pathophysiology of mental disorders. 
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Objeetlve: Validation of the PI-IQ (Patient Health Questionnaire) 
as follow-up instrument in primary care. 
Methods: We included 643 patients with clinical diagnosis of 
Major Depressive Disorder (MDD). At baseline the PI-IQ - a self 
report version of the PRIME-hAD with items identical to those of 
the DSM-IV (ref 1) - w a s  completed (ref 2). Other PHQ-modules 
were also completed. After inclusion patients were treated with 
an SSRI and followed during 12 weeks (3 visits). The PHQ was 
validated using the SCL-90 (commonly used as follow-up scale 
for depression, anxiety and somatization). Evolution of depression 
and comorbidities on the PHQ and SCL-90 were studied, together 
with their impact on work, family and social life. 
Resets: 643 (71,7% female, average age 49,9 years) pa- 
tients completed the stu@. All PHQ and SCL-90 scores (de- 
pression, anxiety, somatization) decreased significantly over time 
(p<0.0001). The more severe the depression, the higher the PI-IQ 
scores at baseline and the faster the decrease over time. A @LMM- 
analysis showed that men had lower PI-IQ depression scores at 
baseline than women (p=0.002) but their recovery was slower 
(p=0.006). The same was seen at the SCL-90: men had lower SCL- 
9 0  depression scores (_p=0.004) but their scores decreased slower 
(p=0.007). However, after 12 weekz of treatment similar scores 
were obtained for both sexes. Older patients had systematically 
lower depression scores (1:)=0.012). The PI-IQ and SCL90 scores 
were standardised on a 0-100 scale in order to compare. The 
evolution over time of the scales was practically the same for the 
sections "depression" (Table 1) and "anxiety". For somatization 
there was a slightly different evolution: SCL-90 had lower somatic 
end-score~ than PHQ. Nigher scores on PHQ and SCL-90 for 
depression, anxiety and somatic disease all resulted in higher 
Sheehan 4, 5 and 6-scores. The scores decreased over time 
(p<0.0001). In older patients (p<0.0001) and patients living alone 
a significant slower decrease was seen on the Sheehan 4 whereas 
evolution of Sheehan 5 and 6 (impact on social and family life) 
did not depend on a W covariate. The strongest evolution on all 
scales was seen after 4 weeks of treatment with further reduction 
of the scores after 8 weeks and remained stable during further 
treamaent. 
Baseline Week 4 Week 8 Week 12 
SOL-90 rnearckSD 100 79.5+30.2 67.94-32.0 65.04-32.1 
PHQ mearcESD 100 79.54-21.8  69.34-24.9 64.84-23.9 
Conclmion: The PHQ and SCL-90 show a comparable evolu- 
tion over time, meaning that the PHQ entails comparable moni- 
toring capacity for follow-up on depression and comorbidities as 
the SCL-90. 
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Bael%mmma& The classical antidepressant amitriptyline (At) is a 
strong inhibitor of serotonin (5HT) uptake in platelets or brain 
synaptosomes. I-Iowever, the percentage of serotonin transporter 
(5HTT) inhibition in the brain of patients during a typical course 
of At treatment is unknown. 
Objeetiw: To test the inhibiting effect of At  in brain regions 
with high or low density of 5HTTs in oioo using the new high 
affinity radioligand 123I-ADAM and SPECT. A second aim was 
to assess the relationship between lz3I-ADAM binding reduction 
and plasma At levels and 5HT uptake inhibition in platelets. 
Material and Metl~ds: Eleven normotensive and non- 
medicated subjects (5 healthy controls and 6 psychiatric patients 
according to ICD-10 criteria) were investigated twice, before and 
after 7 days of At administration (50 mg/day). SPECT images 
were obtained 4h post injection of lz3I-ADAM. Regions of in- 
terest (ROI) were drawn manually in areas corresponding to the 
midbrain, frontal cortex and cerebellum. The measured activities 
